Karyopharm Therapeutics (KPTI) has released an update.
Karyopharm Therapeutics Inc. has successfully regained compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Global Select Market. After previously failing to meet the $1.00 per share minimum, the company’s stock maintained a closing bid price above this threshold for the necessary period, rectifying its non-compliance and stabilizing its standing in the stock market.
For further insights into KPTI stock, check out TipRanks’ Stock Analysis page.
